RESULTS FROM PHASE IB STUDY OF TEBENTAFUSP (TEBE) IN COMBINATION WITH DURVALUMAB (DURVA) AND/OR TREMELIMUMAB (TREME) IN METASTATIC CUTANEOUS MELANOMA (MCM)

¹Omid Hamid*, ²Jessica Hassel, ³Alexander Shoushtari, ⁴Friedegund Meier, ⁵Todd Bauer, ⁶April Salama, ⁷John Kirkwood, ⁸Paolo Ascierto, ⁹Paul Lorigan, ¹⁰Cornelia Mauch, ¹¹Marilena Orloff, ¹²Jeff Evans, ¹³Ramakrishna Edukulla, ¹³Chris Holland, ¹³Shaad Abdullah, ¹³Renee Mundy, ¹⁴Mark Middleton. ¹The Angeles Clinic and Research Institute, Los Angeles, CA, USA; ²University Hospital Heidelberg, Heidelberg, Germany; ³Memorial Sloan-Kettering Hospital, New York, NY, USA; ⁴University Hospital Carl Gustav Carus, Dresden, Germany; ⁵Tennessee Oncology, Franklin, TN, USA; ⁶Duke University Health System, Durham, NC, USA; ⁷University of Pittsburgh Medical Center, Pittsburgh, PA, USA; ⁸Fondazione IRCCS Istituto Nazionale dei Tumori, Napoli, Italy; ⁹The Christie NHS Foundation Trust, Manchester, UK; ¹⁰University Hospital Cologne, Cologne, Germany; ¹¹Sidney Kimmel Cancer Center, Philadelphia, PA, USA; ¹²Beatson West of Scotland Cancer Centre, Glasgow, UK; ¹³Immunocore, Rockville, USA; ¹⁴University of Oxford, Oxford, UK

Background Tebe, a T cell receptor fused to an anti-CD3 effector, can redirect T cells to target gp100+ cells and in Ph3, demonstrated overall survival (OS) benefit as monotherapy in metastatic uveal melanoma. In Ph2, any tumor shrinkage (44% of patients) was a better predictor of OS than response rate. In Ph1, Tebe had monotherapy activity in mCM, also a gp100+ tumor, with 1-year OS ~74% in PD-1 naïve mCM. A Ph1 dose escalation of tebe with durva (anti-PD-L1) and/or treme (anti-CTLA4) was conducted in pre-treated mCM [NCT02535078], with nearly all patients having prior PD1-treatment, and where recently reported therapies have 1-yr OS of ~55%.

Methods Heavily pre-treated HLA-A2+ mCM patients received weekly IV tebe alone (Arm 4) or with increasing doses of durva and/or treme (Arm 1–3) administered IV monthly starting day 15 of each cycle. Primary objective was to identify RP2D of combination therapy. Secondary objectives included adverse events (AE) and efficacy.

Results 112 pts received ≥1 tebe dose. Median age was 59, 77% were ECOG 0, and 37% were BRAFm (of which 71% received prior BRAFi/MEKi). 91% of pts were 2L+, while 74% were 3L+. 103 (92%) received prior PD-1 inhibitor, of which 87% also received prior ipilimumab. 43 pts received tebe + durva (Arm 1), 13 received tebe + treme (Arm 2), 29 received triplet therapy (Arm 3), and 27 received tebe alone (Arm 4). Maximum target doses of tebe (68 mcg) + durva (20 mg/kg) and treme (1 mg/kg) were tolerated. MTD was not formally identified for any arm. Two DLTs occurred: prolonged grade 3 rash (Arm 1) and grade 2 diarrhea leading to treatment delay (Arm 2). Related AEs that were Grade ≥3 or led to discontinuations were: 44%/0% (Arm 1), 23%/0% (Arm2), 38%/7% (Arm3), 26%/4% (Arm 4). There were no treatment-related deaths. In prior PD-1 pts, tumor shrinkage occurred in 36% and 1-yr OS was 68%. Of 51 evaluable PD-1 resistant pts (best response CR/PR/SD to prior PD1), tumor shrinkage occurred in 28% and 1-yr OS was 73% (figure 1). In 35 evaluable PD-1 refractory pts (prior best response PD), tumor shrinkage occurred in 49% and 1-yr OS was 61%. For 38 prior PD-1 pts who received ≥10mg/kg durva, 1-yr OS was 81%.

Abstract 546 Figure 1 % tumor change from baseline in evaluable patients with known response to prior PD1 exposure

Conclusions Tebe with anti-PD-L1 and/or anti-CTLA4 had an acceptable safety profile. Tebe + durva demonstrated durable tumor shrinkage and promising 1-yr OS rates in prior-PD1 treated mCM relative to recent reports.

Trial Registration NCT02535078

Ethics Approval The institutional review board or independent ethics committee at each center approved the trial. The trial was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines.

<http://dx.doi.org/10.1136/jitc-2021-SITC2021.546>